News and Media
Findings from new 3 year clinical trial presented for the first time at Vitafoods Geneva, May 22nd
Don’t miss the opportunity to listen to Professor Cees Vermeer present the outcomes of the 3-year clinical trial investigating beneficial effects of natural vitamin K2 (MenaQ7) on bone and vascular health.
MenaQ7 is the first Vitamin K supplement with demonstrated health effects at nutritionally relevant doses.
When: Tuesday, May 22nd at 11:05
Where: Seminar Theatre, Vitafoods Geneva
Topic: MenaQ7: the first Vitamin K supplement with demonstrated health effects at nutritionally relevant doses. Findings from new 3-year clinical trail
“The results from the 3 year human study on MenaQ7® are encouraging. This is the first time in history such effects have been scientifically documented with natural vitamin K2. It is an essential step for NattoPharma to get this confirmation, and we will actively use the findings together with our customers and partners to improve our commercial platform. NattoPharma has made a significant investment in this study and is working on expanding its partnerships with leading companies commercializing MenaQ7® in the supplement and functional food markets throughout the world.” - Peter Carlsson (Former CEO)
Read the press release here
In April 2008, NattoPharma started a clinical intervention study with 244 postmenopausal women randomized to receive either MenaQ7® or placebo. The study has been conducted at VitaK at the Maastricht University in the Nederland’s and lead by Associate Professor of Biochemistry Cees Vermeer. The aim of the study was to investigate the effects of a sustained intake of a low dose (180 mcg) of natural vitamin K2 (MenaQ7®) on both bone and vascular health parameters. Final results of this clinical study are expected to be released during 2012 and are likely to generate several scientific publications. The results will also be used for the important regulatory work worldwide.
For the Press
Director of Communications
(+1) 609-454-2992 x 220